The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Kartos Therapeutics
 
Consulting or Advisory Role - Bristol-Myers Squibb; Highlight Therapeutics; Novartis; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Research Funding - Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; MSD; Novartis; Pfizer; Pierre Fabre; Roche
NOTOS: A pivotal study of navtemadlin, a first-in-class mouse double minute 2 inhibitor (MDM2i), in patients (pts) with TP53 wild-type (TP53WT) Merkel cell carcinoma (MCC) for whom anti PD-1/L1 therapy has failed.
 
Michael K.K. Wong
Consulting or Advisory Role - Castle Biosciences; Regeneron; Replimune
 
Melissa Amber Burgess
Consulting or Advisory Role - Rain Therapeutics; SpringWorks Therapeutics
Research Funding - Merck
 
Sunandana Chandra
Honoraria - Array BioPharma; Bristol Myers Squibb; EMD Serono; Exicure; Novartis; Pfizer; Sanofi/Regeneron
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Exicure; Novartis; Pfizer; Sanofi/Regeneron
Research Funding - Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); exicure (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Regeneron (Inst)
 
Leslie Anne Fecher
Consulting or Advisory Role - Elsevier; Hoosier Cancer Research Network; Via Oncology
Research Funding - Bristol-Myers Squibb (Inst); Kartos Therapeutics (Inst); Pfizer/Array (Inst); Pfizer/EMD Serono (Inst)
Travel, Accommodations, Expenses - AIM at Melanoma Foundation
Other Relationship - Pfizer/Array
(OPTIONAL) Uncompensated Relationships - American Association of Clinical Endocrinology; ASCO; NCCN
 
Caroline Gaudy-Marqueste
Honoraria - Blueprint Medicines; BMS france; MSD Oncology; Pierre Fabre
Consulting or Advisory Role - Pierre Fabre
Travel, Accommodations, Expenses - BMS France; MSD Oncology; Pierre Fabre
 
Ann W. Silk
Consulting or Advisory Role - Instil Bio; Signatera
Research Funding - Biohaven Pharmaceuticals (Inst); Checkmate Pharmaceuticals (Inst); Morphogenesis (Inst); Replimune (Inst); Shattuck Labs (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Glenn J. Hanna
Employment - Dana-Farber Cancer Institute
Honoraria - Bristol-Myers Squibb; Kura Oncology
Consulting or Advisory Role - Bicara Therapeutics; Boxer Capital; Bristol-Myers Squibb; Exicure; General Catalyst; KSQ Therapeutics; Kura Oncology; Merck; Naveris; Prelude Therapeutics; Rain Therapeutics; Remix Therapeutics; Sanofi; SIRPant Immunotherapeutics
Research Funding - Actuate Therapeutics (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Conquer Cancer, the ASCO Foundation; Elevar Therapeutics (Inst); Exicure (Inst); Gateway for Cancer Research; Genzyme (Inst); GlaxoSmithKline (Inst); Kartos Therapeutics (Inst); Kite/Gilead (Inst); Kite/Gilead (Inst); NantKwest, (Inst); Regeneron (Inst); Secura Bio (Inst); V Foundation
Expert Testimony - Aaronson Rappaport Feinstein & Deutsch; Ahmuty, Demers, & McManus; Wilson Elser Moskowitz Edelman & Dicker, LLP
 
Celeste Lebbe
Honoraria - Amgen; Bristol-Myers Squibb; Incyte; MSD; Novartis; Pfizer; Pierre Fabre; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Serono; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Sanofi
Other Relationship - Avantis Medical Systems; BMS; InflaRx; Jazz Pharmaceuticals; MSD; Novartis; Pierre Fabre; Sanofi
 
Gaëlle Quéreux
No Relationships to Disclose
 
Guilherme Rabinowits
Consulting or Advisory Role - BostonGene; Castle Biosciences; replimune; Sanofi/Regeneron
 
Dirk Schadendorf
Honoraria - 4SC; Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Japan; Erasca, Inc; immatics; Immunocore; InflarxGmbH; LabCorp; Merck Serono; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Novigenix; Pamgene; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sanofi/Regeneron; Seagen; Sun Pharma; Ultimovacs
Consulting or Advisory Role - Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Erasca, Inc; immatics; Immunocore; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Pierre Fabre; Replimune; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
 
Caroline Dutriaux
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
 
Carola Berking
Honoraria - Almirall Hermal GmbH; Bristol-Myers Squibb; LEO Pharma; MSD; Novartis; Sanofi/Aventis
Consulting or Advisory Role - Almirall Hermal GmbH; Bristol-Myers Squibb; Immunocore; InflaRx; MSD; Novartis; Pierre Fabre; Sanofi/Aventis; Sanofi/Regeneron
Research Funding - Almirall Hermal GmbH (Inst); Bristol-Myers Squibb (Inst); immatics (Inst); InflaRx (Inst); IO Biotech (Inst); Kartos Therapeutics (Inst); Pfizer (Inst)
 
Juan Martin Liberal
No Relationships to Disclose
 
Paolo Antonio Ascierto
Consulting or Advisory Role - 4SC; AstraZeneca; Bayer; Bio-AI Health; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Idera; Immunocore; Italfarmaco; ITeos Therapeutics; Lunaphore Technologies; Medicenna; Merck Serono; Merck Sharp & Dohme; Nektar; Nouscom; Novartis; OncoSec; Pfizer; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sandoz; Sanofi; Seagen; Sun Pharma; Ultimovacs; ValoTx
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bio-AI Health; Pfizer; Replimune
 
Emily Houlihan
No Relationships to Disclose
 
Kim Steinmann
No Relationships to Disclose
 
Tiffanie Chan
Employment - Kartos Therapeutics
 
Wayne P. Rothbaum
Leadership - Iovance Biotherapeutics
Stock and Other Ownership Interests - Acerta Pharma; Iovance Biotherapeutics; Kartos Therapeutics; Telios
Patents, Royalties, Other Intellectual Property - Kartos Therapeutics; Quogue IP Holdings; Telios
 
Ciara Marie Kelly
Employment - Daichii Sankyo (I)
Stock and Other Ownership Interests - daichii sankyo (I)
Consulting or Advisory Role - ChemoCentryx; Exicure; Immunicum; Immunicum; Kartos Therapeutics; SERVIER
Research Funding - AGIOS (Inst); Amgen (Inst); Curadev (Inst); Exicure (Inst); INCYTE (Inst); Kartos Therapeutics (Inst); Merck (Inst); Regeneron (Inst); Servier (Inst); xencor (Inst)